Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries
Journal – JCO Global Oncology
Article type – Journal research article – Clinical research
Publication date – Apr – 2021
Authors – Fernando S. M. Monteiro, Fabio A. Schutz, Igor A. P. Morbeck, Diogo A. Bastos, Fernando V. de Padua, Leonardo A. G. A. Costa, Manuel C. Maia, Jose A. Rinck Jr, Stenio de Cassio Zequi, Karine M. da Trindade, Wladimir Alfer Jr, William C. Nahas, Lucas V. dos Santos, Robson FerrignoDiogo A. R. da Rosa, Juan P. Sade, Francisco J. Orlandi,Fernando N. G. de Oliveira, Andrey Soares
Keywords – castration-sensitive PCa, consensus, Prostate Cancer
Open access – Yes
Speciality – Surgical oncology, Urology surgery
World region Global
Language – English
Submitted to the One Surgery Index on April 27, 2021 at 4:03 am
To present a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer (PCa) acquired through a questionnaire administered to 99 PCa experts from developing countries during the Prostate Cancer Consensus Conference for Developing Countries.
A total of 27 questions were identified as related to this topic from more than 300 questions. The clinician’s responses were tallied and presented in a percentage format. Topics included the use of imaging for staging biochemical recurrence, treatment recommendations for three different clinical scenarios, the field of radiation recommended, and follow-up. Each question had 5-7 relevant response options, including “abstain” and/or “unqualified to answer,” and investigated not only recommendations but also if a limitation in resources would change the recommendation.
For most questions, a clear majority (> 50%) of clinicians agreed on a recommended treatment for imaging, treatment scenarios, and follow-up, although only a few topics reached a consensus > 75%. Limited resources did affect several areas of treatment, although in many cases, they reinforced more stringent criteria for treatment such as prostate-specific antigen values > 0.2 ng/mL and STAMPEDE inclusion criteria as a basis for recommending treatment.
A majority of clinicians working in developing countries with limited resources use similar cutoff points and selection criteria to manage patients treated for biochemically recurrent castration-sensitive PCa.
OSI Number – 21063